Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Potassium citrate + sodium citrate hydrate is an oral fixed-dose alkalinizing medicine containing two citrate salts. Citrate is metabolized to bicarbonate, increasing systemic and urinary alkalinity and urinary citrate availability. It is marketed in Japan as Uralyt-U and Uralyt for improvement of acidic urine associated with gout or hyperuricemia and for improvement of metabolic acidosis. It has also been clinically studied for prevention of calcium stone recurrence and contrast-induced nephropathy, while preclinical studies have examined tumor-microenvironment alkalinization and chemotherapy-induced peripheral neuropathy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on potassium citrate + sodium citrate hydrate.